First Mercantile Trust Co. bought a new stake in Smith & Nephew plc (NYSE:SNN) during the third quarter, Holdings Channel.com reports. The firm bought 13,375 shares of the medical equipment provider’s stock, valued at approximately $644,000.

A number of other large investors have also bought and sold shares of the business. Fiduciary Management Inc. WI raised its position in Smith & Nephew by 2.9% in the second quarter. Fiduciary Management Inc. WI now owns 8,420,997 shares of the medical equipment provider’s stock valued at $366,650,000 after purchasing an additional 233,761 shares during the period. Iridian Asset Management LLC CT raised its position in Smith & Nephew by 13.5% in the second quarter. Iridian Asset Management LLC CT now owns 2,639,567 shares of the medical equipment provider’s stock valued at $114,927,000 after purchasing an additional 313,374 shares during the period. WCM Investment Management LLC purchased a new stake in Smith & Nephew in the third quarter valued at $123,389,000. Nuance Investments LLC raised its position in Smith & Nephew by 29.0% in the second quarter. Nuance Investments LLC now owns 1,531,811 shares of the medical equipment provider’s stock valued at $66,695,000 after purchasing an additional 344,052 shares during the period. Finally, FMR LLC raised its position in Smith & Nephew by 640.8% in the first quarter. FMR LLC now owns 1,341,034 shares of the medical equipment provider’s stock valued at $53,788,000 after purchasing an additional 1,160,015 shares during the period. Institutional investors own 9.02% of the company’s stock.

Shares of SNN stock traded down $0.16 on Friday, hitting $42.54. The stock had a trading volume of 167,548 shares, compared to its average volume of 1,022,951. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.00 and a quick ratio of 0.96. The firm has a market capitalization of $18.74 billion, a P/E ratio of 21.06, a P/E/G ratio of 2.90 and a beta of 0.23. Smith & Nephew plc has a 1 year low of $35.39 and a 1 year high of $48.93. The company’s 50 day moving average price is $45.95 and its 200-day moving average price is $44.41.

The company also recently disclosed a — dividend, which was paid on Wednesday, October 30th. Investors of record on Friday, October 4th were issued a $0.288 dividend. The ex-dividend date of this dividend was Thursday, October 3rd. This represents a dividend yield of 1.5%. Smith & Nephew’s dividend payout ratio is presently 27.72%.

A number of equities research analysts have commented on SNN shares. Berenberg Bank upgraded Smith & Nephew from a “hold” rating to a “buy” rating in a research report on Tuesday, July 23rd. Zacks Investment Research upgraded Smith & Nephew from a “sell” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, ValuEngine downgraded Smith & Nephew from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $27.50.

Smith & Nephew Profile

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Further Reading: How to trade on quiet period expirations

Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNN).

Institutional Ownership by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.